Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 0.73 |
| ▸ | KIT | P10721 | 3/20 | 0.59 |
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907678 | 0.98 | PDGFRB (0.74) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL3367274 | 0.89 | PDGFRB (0.64) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL906248 | 0.88 | PDGFRB (0.75) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL6704362 | 0.88 | PDGFRB (0.79) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL6704570 | 0.88 | PDGFRB (0.79) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL3364862 | 0.87 | PDGFRB (0.65) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL5907679 | 0.86 | PDGFRB (0.79) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL6703372 | 0.85 | PDGFRB (0.80) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL5907743 | 0.85 | PDGFRB (0.78) | PDGFRBKITFLT3PDGFRA | |
| SCHEMBL3366898 | 0.85 | PDGFRB (0.78) | PDGFRBKITFLT3PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | claimed |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1309569-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016362-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | WNK2, CDK5, WNK1 | PDGFRB 6/4885KIT 597/4885FLT3 369/4885 |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | WNK2, CDK5, WNK1 | PDGFRB 7/4885KIT 495/4885FLT3 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.